Concepedia

Lacey Padrón

LP

Statistics

Publications

3

Citations

380

H-Index

3

Active since

2022

Affiliations

Parker Institute for Cancer Immunotherapy(Current)

University of California, San Francisco

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Stanford University

Lacey Padrón is an author at Parker Institute for Cancer Immunotherapy specializing in metastatic disease treatment, immunotherapy for solid tumors, and pancreatic cancer pharmacotherapy.

ORCID

Publications per year

2022–2025

3

Publications

3

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Lacey Padrón, Deena M. Maurer, Mark H. O’Hara et al. · Nature Medicine · 2022 · 350 citations · Full text

, , +15

Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study

Zoe Quandt, Anastasia Lucas, Samantha I. Liang et al. · Journal for ImmunoTherapy of Cancer · 2025 · 17 citations · Full text

, , +17

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma

Jacob E. Till, Lee McDaniel, Changgee Chang et al. · Nature Communications · 2024 · 13 citations · Full text

, , +17

1–3 of 3